pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

540 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT943Endpoints724BioPharma Dive278BioSpace171onclive165Fierce Biotech160globenewswire health73raps
therapy area
allOncology5480Rare Disease1197Cardiology1024Hematology898Immunology896Pulmonology735Vaccines
  • Tarsus to acquire eye-drug startup Alkeus in up to $800 million deal
    Tarsus Pharmaceuticals announced Thursday that it will buy Alkeus Pharmaceuticals for up to $800 million, consisting of $270 million in cash and $180 million in stock. The agreement also provides…
    BioPharma Dive · 6d agoDealPositive↗ source
  • Erica Schwartz confirmed as CDC director after year-long leadership void
    Senate confirmed Erica Schwartz, a public-health veteran and vaccine supporter, as the new head of the CDC. She takes over an agency that has operated without a permanent director for almost a yea…
    BioPharma Dive · 6d agoNeutral↗ source
← prev
page 2 of 22
next →
58
fda recalls37
fda medwatch28
fda press24
720
Psychiatry & CNS669
Endocrinology & Metabolism332
Ophthalmology329
Pain320
Infectious Disease314
  • LifeMine secures $263M to advance fungal-derived organ transplant drug
    LifeMine Therapeutics announced it has closed two venture financings that together raised $263 million. The capital will be used to push its experimental therapy, LIFE-001, further along the develo…
    BioPharma Dive · 6d agoDealPositive↗ source
  • Cardiac biotech Braveheart raises $382.5M in IPO, launches on Nasdaq as BRVE
    Braveheart Bio, a cardiac drug developer, priced its initial public offering on Wednesday and secured $382.5 million in proceeds. The company sold about 21.2 million shares at $18 each, exceeding t…
    BioPharma Dive · 6d agoDealPositive↗ source
  • Tiziana Life Sciences CEO Ivor Elrifi buys 321,423 shares, raising his stake to 4.79 million
    Tiziana Life Sciences announced that its chief executive, Ivor Elrifi, purchased 321,423 common shares of the company on NASDAQ at $1.00 per share. The transaction brings Elrifi’s total ownership…
    globenewswire health · 6d agoDealPositive↗ source
  • Novo Nordisk reports board and executive share transactions under EU market abuse rules
    On August 6, 2026 Novo Nordisk issued a company announcement detailing share transactions made by members of its board, senior executives and their close associates in line with Article 19 of EU Re…
    globenewswire health · 6d agoRegulatoryNeutral↗ source
  • Tiziana Life Sciences CEO Ivor Elrifi boosts stake, buying 321,423 shares at $1 each
    Tiziana Life Sciences announced that its chief executive officer, Ivor Elrifi, purchased 321,423 common shares of the company on NASDAQ at $1.00 per share. The purchase raises his total holding to…
    globenewswire health · 6d agoDealPositive↗ source
  • Novo Nordisk board members disclose share vesting transactions
    Novo Nordisk issued a regulatory announcement on 6 August 2026 detailing share transactions by its board members, executives and related persons, as required by EU market abuse regulation. The fil…
    globenewswire health · 6d agoRegulatoryNeutral↗ source
  • InstallatørGruppen reports insider share transaction involving board members' associate
    InstallatørGruppen A/S has filed a Market Abuse Regulation (EU) No. 596/2014 notification under article 19, disclosing a recent share transaction. The transaction was executed by Absalon Holdings…
    globenewswire health · 6d agoRegulatoryNeutral↗ source
  • InstallatørGruppen reports share transaction by board linked entity Absalon Holdings
    InstallatørGruppen A/S filed a notification under the EU Market Abuse Regulation, article 19, to disclose a share transaction involving a person discharging managerial responsibilities and their cl…
    globenewswire health · 6d agoRegulatoryNeutral↗ source
  • Lilly beats forecasts while Novo Nordisk misses sales and trial targets
    Eli Lilly reported second-quarter revenue of nearly $23 billion, up 48% year-over-year, easily surpassing analysts’ $20.6 billion estimate. The boost came from continued strength of its tirzepatide…
    BioPharma Dive · 7d agoEarningsNeutral↗ source
  • Attovia Therapeutics raises $289 million in IPO to fund antibody-drug research for skin and inflammatory diseases
    Attovia Therapeutics completed an IPO raising $289 million, selling 17 million shares at $17 each and valuing the company at $767 million. Shares will begin trading on Nasdaq under the ticker ATTO.…
    BioPharma Dive · 7d agoDealPositive↗ source
  • FDA approves Orzeyful, first drug to treat all symptoms of narcolepsy type 1
    The U.S. Food and Drug Administration announced on August 5, 2026 that it has approved Orzeyful (oveporexton) tablets for adults with narcolepsy type 1. Orzeyful is the first therapy cleared to tr…
    fda press · 7d agoApprovalPositive↗ source
  • Expedition Therapeutics secures $115M Series B to advance China-origin COPD drug
    Expedition Therapeutics, a biotech that licenses drugs from Chinese firms, announced a $115 million Series B financing that will fund mid-stage testing of its experimental COPD candidate. The fund…
    BioPharma Dive · 7d agoDealPositive↗ source
  • Gilead reports modest sales rise but analysts question future growth beyond HIV drugs
    Gilead's second‑quarter results showed total product revenue of $7.6 billion, up 8% year‑over‑year. The company's two leading HIV treatments, Biktarvy and Descovy, together generated about $5.7 bi…
    BioPharma Dive · 7d agoEarningsNeutral↗ source
  • AL Sydbank discloses share transactions by managers and related persons under MAR
    AL Sydbank issued a company announcement (No 41/2026) on 5 August 2026, informing the market of share transactions carried out by its managers and persons closely associated with them. The disclos…
    globenewswire health · 7d agoRegulatoryNeutral↗ source
  • Danske Bank corrects placement of English PDF in transaction disclosure
    The bank originally posted a notice that attached both the Danish and English PDF files to the Danish version of its website. A correction has now moved the English PDF to the English version of th…
    globenewswire health · 7d agoRegulatoryNeutral↗ source
  • Danske Bank corrects website link, moves English PDF to English page for shareholding report
    A correction notice was issued for Danske Bank A/S regarding the placement of an English PDF document on its website. The original announcement had both Danish and English PDFs attached under the…
    globenewswire health · 7d agoRegulatoryNeutral↗ source
  • Danske Bank corrects website to place English PDF with share buyback filing
    Danske Bank issued a correction notice stating that the English version of a PDF document has been relocated on its website. The amendment moves the English PDF from the Danish page to the dedicat…
    globenewswire health · 7d agoRegulatoryNeutral↗ source
  • AL Sydbank reports insider share transactions by senior staff and relatives
    AL Sydbank issued a market abuse regulation disclosure detailing share transactions by its senior employees and their close associates. The filing references attached tables that list the specific…
    globenewswire health · 7d agoNeutral↗ source
  • Danske Bank corrects webpage to place English transaction PDF under English version
    The bank has updated its online notification page so that the English PDF document is now attached under the English version of the site, rather than being listed only under the Danish version. Th…
    globenewswire health · 7d agoRegulatoryNeutral↗ source
  • AL Sydbank reports insider share transactions by senior staff and relatives
    AL Sydbank issued a corporate announcement on 5 August 2026, disclosing share transactions made by its senior employees and their close relatives. The disclosure is made in compliance with Article…
    globenewswire health · 7d agoRegulatoryNeutral↗ source
  • AL Sydbank reports manager and associate share transactions under Market Abuse Regulation
    AL Sydbank has issued a company announcement detailing recent share transactions carried out by its managers and individuals closely linked to them. The disclosure is made under Article 19 of the…
    globenewswire health · 7d agoRegulatoryNeutral↗ source
  • Danske Bank corrects webpage to place English PDF under English version for share buy-back disclosure
    A correction notice was issued for Danske Bank A/S regarding the placement of an English PDF on its website. The original posting had both Danish and English PDFs attached under the Danish version…
    globenewswire health · 7d agoNeutral↗ source
  • Danske Bank corrects webpage to place English PDF in English section
    A correction has been issued for a previous notification concerning Danske Bank A/S. The original posting attached both Danish and English PDF files under the Danish version of the page. The corre…
    globenewswire health · 7d agoNeutral↗ source